Hologic (HOLX) Stock Forecast & Price Target

Compare

974 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

HOLX Analyst Ratings

Moderate Buy

6 Buy

8 Hold

0 Sell

Based on 14 analysts giving stock ratings to

Hologic

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

HOLX Stock 12 Month Forecast

Average Price Target

$67.40

▲(5.28%Upside)

Based on 14 Wall Street analysts offering 12 month price targets for Hologic in the last 3 months. The average price target is $67.40 with a high forecast of $71.00 and a low forecast of $60.00. The average price target represents a 5.28% change from the last price of $64.02.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"56":"$56","63":"$63","70":"$70","77":"$77","84":"$84"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":71,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$71.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":67.4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$67.40</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":60,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$60.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[56,63,70,77,84],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,65.33,65.76615384615384,66.20230769230768,66.63846153846154,67.07461538461538,67.51076923076923,67.94692307692307,68.38307692307693,68.81923076923077,69.25538461538461,69.69153846153846,70.12769230769231,70.56384615384616,{"y":71,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,65.33,65.48923076923077,65.64846153846153,65.8076923076923,65.96692307692308,66.12615384615384,66.28538461538461,66.44461538461539,66.60384615384616,66.76307692307692,66.9223076923077,67.08153846153847,67.24076923076923,{"y":67.4,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,65.33,64.92,64.51,64.1,63.69,63.28,62.87,62.46,62.05,61.64,61.23,60.82,60.41,{"y":60,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":74.1,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":83.2,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":81.24,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":80.56,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":82.33,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":79,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":72.09,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":72.14,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.39,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":61.38,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.28,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":62.01,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.33,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$71.00

Average Price Target$67.40

Lowest Price Target$60.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$69

Hold

7.78%

Upside

Downgraded

07/16/25

Hologic's solid financial health and strategic focus on non-product revenue growth provide a stable base. However, recent revenue declines, geopolitical challenges, and higher relative valuation dampen the overall outlook. Technical indicators suggest mixed momentum, requiring cautious consideration by investors.

Anthony PetroneMizuho Securities

Mizuho Securities

$65→$70

Buy

9.34%

Upside

Upgraded

07/16/25

Mizuho Securities Keeps Their Buy Rating on Hologic (HOLX)

Patrick B DonnellyCiti

Citi

―

Buy

―

Upgraded

07/09/25

Citi upgrades Hologic (HOLX) to a Buy

Vijay KumarEvercore ISI

Evercore ISI

$62→$68

Hold

6.22%

Upside

Reiterated

07/08/25

Evercore ISI Sticks to Their Hold Rating for Hologic (HOLX)

Conor McNamaraRBC Capital

RBC Capital

$70

Hold

9.34%

Upside

Reiterated

06/30/25

Hologic (HOLX) Receives a Hold from RBC Capital

Michael MatsonNeedham

Needham

―

Hold

―

Reiterated

05/27/25

Hologic (HOLX) Gets a Hold from Needham

Mason CarricoStephens

Stephens

$77→$70

Buy

9.34%

Upside

Reiterated

05/13/25

Hologic price target lowered to $70 from $77 at StephensHologic price target lowered to $70 from $77 at Stephens

Tejas SavantMorgan Stanley

Morgan Stanley

$65

Hold

1.53%

Upside

Reiterated

05/05/25

Hologic's Hold Rating: Balancing Growth in Diagnostics with Challenges in Breast Health and Geopolitical Pressures

Dan LeonardUBS

UBS

$80→$65

Hold

1.53%

Upside

Reiterated

05/02/25

Hologic (HOLX) PT Lowered to $65 at UBSUBS analyst Elizabeth Garcia lowered the price target on Hologic (NASDAQ: HOLX) to $65.00 (from $80.00) while maintaining a Neutral rating.

Tycho PetersonJefferies

Jefferies

$78→$65

Hold

1.53%

Upside

Reiterated

05/02/25

Hologic (HOLX) PT Lowered to $65 at JefferiesJefferies analyst Tycho Peterson lowered the price target on Hologic (NASDAQ: HOLX) to $65.00 (from $78.00) while maintaining a Hold rating.

Andrew BrackmannWilliam Blair

William Blair

―

Buy

―

Reiterated

05/02/25

Analysts Conflicted on These Healthcare Names: Blueprint Medicines (NASDAQ: BPMC), Envista Holdings (NYSE: NVST) and Hologic (NASDAQ: HOLX)

Casey WoodringJ.P. Morgan

J.P. Morgan

$85→$70

Buy

9.34%

Upside

Reiterated

05/02/25

J.P. Morgan Keeps Their Buy Rating on Hologic (HOLX)

Ryan ZimmermanBTIG

BTIG

―

Hold

―

Reiterated

05/02/25

BTIG Sticks to Its Hold Rating for Hologic (HOLX)

Andrew CooperRaymond James

Raymond James

$90→$71

Buy

10.90%

Upside

Reiterated

05/02/25

Hologic price target lowered to $71 from $90 at Raymond JamesHologic price target lowered to $71 from $90 at Raymond James

Puneet SoudaLeerink Partners

Leerink Partners

$60

Hold

-6.28%

Downside

Reiterated

05/01/25

Hologic's Financial Outlook: Hold Rating Amid Revenue Decline and Tariff Challenges

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$69

Hold

7.78%

Upside

Downgraded

07/16/25

Anthony PetroneMizuho Securities

Mizuho Securities

$65→$70

Buy

9.34%

Upside

Upgraded

07/16/25

Mizuho Securities Keeps Their Buy Rating on Hologic (HOLX)

Patrick B DonnellyCiti

Citi

―

Buy

―

Upgraded

07/09/25

Citi upgrades Hologic (HOLX) to a Buy

Vijay KumarEvercore ISI

Evercore ISI

$62→$68

Hold

6.22%

Upside

Reiterated

07/08/25

Evercore ISI Sticks to Their Hold Rating for Hologic (HOLX)

Conor McNamaraRBC Capital

RBC Capital

$70

Hold

9.34%

Upside

Reiterated

06/30/25

Hologic (HOLX) Receives a Hold from RBC Capital

Michael MatsonNeedham

Needham

―

Hold

―

Reiterated

05/27/25

Hologic (HOLX) Gets a Hold from Needham

Mason CarricoStephens

Stephens

$77→$70

Buy

9.34%

Upside

Reiterated

05/13/25

Hologic price target lowered to $70 from $77 at StephensHologic price target lowered to $70 from $77 at Stephens

Tejas SavantMorgan Stanley

Morgan Stanley

$65

Hold

1.53%

Upside

Reiterated

05/05/25

Hologic's Hold Rating: Balancing Growth in Diagnostics with Challenges in Breast Health and Geopolitical Pressures

Dan LeonardUBS

UBS

$80→$65

Hold

1.53%

Upside

Reiterated

05/02/25

Hologic (HOLX) PT Lowered to $65 at UBSUBS analyst Elizabeth Garcia lowered the price target on Hologic (NASDAQ: HOLX) to $65.00 (from $80.00) while maintaining a Neutral rating.

Tycho PetersonJefferies

Jefferies

$78→$65

Hold

1.53%

Upside

Reiterated

05/02/25

Hologic (HOLX) PT Lowered to $65 at JefferiesJefferies analyst Tycho Peterson lowered the price target on Hologic (NASDAQ: HOLX) to $65.00 (from $78.00) while maintaining a Hold rating.

Andrew BrackmannWilliam Blair

William Blair

―

Buy

―

Reiterated

05/02/25

Analysts Conflicted on These Healthcare Names: Blueprint Medicines (NASDAQ: BPMC), Envista Holdings (NYSE: NVST) and Hologic (NASDAQ: HOLX)

Casey WoodringJ.P. Morgan

J.P. Morgan

$85→$70

Buy

9.34%

Upside

Reiterated

05/02/25

J.P. Morgan Keeps Their Buy Rating on Hologic (HOLX)

Ryan ZimmermanBTIG

BTIG

―

Hold

―

Reiterated

05/02/25

BTIG Sticks to Its Hold Rating for Hologic (HOLX)

Andrew CooperRaymond James

Raymond James

$90→$71

Buy

10.90%

Upside

Reiterated

05/02/25

Hologic price target lowered to $71 from $90 at Raymond JamesHologic price target lowered to $71 from $90 at Raymond James

Puneet SoudaLeerink Partners

Leerink Partners

$60

Hold

-6.28%

Downside

Reiterated

05/01/25

Hologic's Financial Outlook: Hold Rating Amid Revenue Decline and Tariff Challenges

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Hologic

1 Month

xxx

Success Rate

9/20 ratings generated profit

Average Return

-0.03%

upgraded a xxx

rating 3 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 45.00% of your transactions generating a profit, with an average return of -0.03% per trade.

3 Months

xxx

Success Rate

8/20 ratings generated profit

Average Return

-0.52%

upgraded a xxx

rating 3 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 40.00% of your transactions generating a profit, with an average return of -0.52% per trade.

1 Year

Andrew CooperRaymond James

Success Rate

6/11 ratings generated profit

Average Return

+3.92%

reiterated a buy rating 3 months ago

Copying Andrew Cooper's trades and holding each position for 1 Year would result in 54.55% of your transactions generating a profit, with an average return of +3.92% per trade.

2 Years

xxx

Success Rate

3/11 ratings generated profit

Average Return

-5.91%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 27.27% of your transactions generating a profit, with an average return of -5.91% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

HOLX Analyst Recommendation Trends

Rating

Mar 25

Apr 25

May 25

Jun 25

Jul 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, HOLX has received 8 Buy Ratings, 13 Hold Ratings, and 0 Sell Ratings. HOLX average Analyst price target in the past 3 months is 67.40.

Each month's total comprises the sum of three months' worth of ratings.

HOLX Financial Forecast

HOLX Earnings Forecast

Next quarter’s earnings estimate for HOLX is $1.05 with a range of $1.04 to $1.08. The previous quarter’s EPS was $1.03. HOLX beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 42.22% of the time in the same period. In the last calendar year HOLX has Preformed in-line its overall industry.

HOLX Sales Forecast

Next quarter’s sales forecast for HOLX is $1.01B with a range of $1.00B to $1.02B. The previous quarter’s sales results were $1.01B. HOLX beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 56.06% of the time in the same period. In the last calendar year HOLX has Preformed in-line its overall industry.

HOLX Stock Forecast FAQ

What is HOLX’s average 12-month price target, according to analysts?

Based on analyst ratings, Hologic’s 12-month average price target is 67.40.

What is HOLX’s upside potential, based on the analysts’ average price target?

Hologic has 5.28% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is HOLX a Buy, Sell or Hold?

Hologic has a consensus rating of Moderate Buy which is based on 6 buy ratings, 8 hold ratings and 0 sell ratings.

What is Hologic’s price target?

The average price target for Hologic is 67.40. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $71.00 ,the lowest forecast is $60.00. The average price target represents 5.28% Increase from the current price of $64.02.

What do analysts say about Hologic?

Hologic’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 14 Wall Streets Analysts.

How can I buy shares of HOLX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Hologic (HOLX) Stock Forecast & Price Target

HOLX Analyst Ratings

HOLX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Hologic

HOLX Analyst Recommendation Trends

HOLX Financial Forecast

HOLX Earnings Forecast

HOLX Sales Forecast

HOLX Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts